Successful use of a janus kinase inhibitor for the treatment of atopic dermatitis

The article presents a clinical report of the use of a new drug of the janus kinase inhibitor, upadacitinib, possessing of the effect on the intracellular JAK/STAT system, the role of which in the pathogenesis of atopic dermatitis (AD) is being actively studied. JAK/STAT includes janus kinases JAK1, JAK2, JAK3, tyrosine kinase, protein-transductor and transcription activator (STAT). When the cytokine interacts with the corresponding receptor, janus kinases phosphorylate STAT proteins inducing transcription of genes that mediate the action of key cytokines to trigger the development of an inflammatory response in the shock organ. Upadacitinib is recommended for uncontrolled AD patients older 12 years. The use of upadacitinib in a 17-year-old patient at a dose of 15 mg in tablets, daily, has shown high efficacy in achieving clinical remission of AD and complete relief of the skin itching.

Contribution:
Revyakina V.A., Larkova I.A. — concept and design of the work;
Mukhortykh V.A., Glukhova E.A., Kuvshinova E.D., Timofeeva A.M. — preparation of the material;
Revyakina V.A., Larkova I.A. — writing the text.
All co-authors — approval of the final version of the article, responsibility for the integrity of all parts of the article.

Acknowledgment. The study had no sponsorship.

Conflict of interest. The authors declare no conflict of interest.

Received: June 07, 2022
Accepted: June 29, 2022
Published: August 30, 2022

1. Roduit C., Frei R., Depner M., Karvonen A.M., Renz H., Braun-Fahrländer C., et al. Phenotypes of atopic dermatitis depending on the timing of onset and progression in childhood. JAMA Pediatr. 2017; 171(7): 655–62. https://doi.org/10.1001/jamapediatrics.2017.0556

2. Khamaganova I.V., Novozhilova O.L., Vorontsova I.V. Epidemiology of atopic dermatitis. Klinicheskaya dermatologiya i venerologiya. 2017; 16(4): 21–5. https://doi.org/10.17116/klinderma201716421-25 (in Russian)

3. Smirnova G.I. Current concepts of atopic dermatitis in children: problems and prospects. Rossiyskiy pediatricheskiy zhurnal. 2017; 20(2): 99–107. https://doi.org/10.18821/1560-9561-2017-20(2)-99-107 (in Russian)

4. Yang Y.B., Gohari A., Lam J. Brief academic review and clinical practice guidelines for pediatric atopic dermatitis. Curr. Pediatr. Rev. 2021; 17(3): 229–37. https://doi.org/10.2174/1573396316999200820163434

5. Mancuso J.B., Lee S.S., Paller A.S., Ohya Y., Eichenfield L.F. Management of severe atopic dermatitis in pediatric patients. J. Allergy Clin. Immunol. Pract. 2021; 9(4): 1462–71. https://doi.org/10.1016/j.jaip.2021.02.017

6. Lar’kova I.A., Glukhova E.A., Revyakina V.A. The efficacy and safety of immunobiological therapy of atopic dermatitis in children. Rossiyskiy pediatricheskiy zhurnal. 2022; 25(1): 46–51. https://doi.org/10.46563/1560-9561-2022-25-1-46-51 (in Russian)

7. Saini S., Pansare M. New insights and treatments in atopic dermatitis. Immunol. Allergy Clin North Am. 2021; 41(4): 653–65. https://doi.org/10.1016/j.iac.2021.07.005

8. Janmohamed S.R., Ring J., Eichenfield L.F., Gutermuth J. Medical algorithm: Treatment of atopic dermatitis in early childhood (part II). Allergy. 2021; 76(1): 407–10. https://doi.org/10.1111/all.14512

9. Klasa B., Cichocka-Jarosz E. Atopic dermatitis – current state of research on biological treatment. J. Mother Child. 2020; 24(1): 53–66. https://doi.org/10.34763/jmotherandchild.2020241.2003.0000010

10. Ghamrawi R., Bell K.A., Balogh E.A., Strowd L.C., Feldman S.R. Current and emerging biologics for the treatment of pediatric atopic dermatitis. Expert. Opin. Biol. Ther. 2020; 20(12): 1435–45. https://doi.org/10.1080/14712598.2021.1840548

11. Revyakina V.A., Taganov A.V., Kuvshinova E.D., Lar’kova I.A., Mukhortykh V.A. Atopic dermatitis, a modern strategy in therapy. Lechashchiy vrach. 2019; (5): 32–7. (in Russian)

12. Siegels D., Heratizadeh A., Abraham S., Binnmyr J., Brockow K., Irvine A.D., et al. Systemic treatments in the management of atopic dermatitis: A systematic review and meta-analysis. Allergy. 2021; 76(4): 1053–76. https://doi.org/10.1111/all.14631

13. Silverberg J.I., Thyssen J.P., Fahrbach K., Mickle K., Cappelleri J.C., Romero W., et al. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. J. Eur. Acad. Dermatol. Venerol. 2021; 35(9): 1797–10. https://doi.org/10.1111/jdv.17351

14. Newsom M., Bashyam A.M., Balogh E.A., Feldman S.R., Strowd L.C. New and emerging systemic treatments for atopic dermatitis. Drugs. 2020; 80(11): 1041–52. https://doi.org/10.1007/s40265-020-01335-7

15. Le M., Berman-Rosa M., Ghazawi F.M., Bourcier M., Fiorillo L., Gooderham M., et al. Systematic review on the efficacy and safety of oral janus kinase inhibitors for the treatment of atopic dermatitis. Front. Med. (Lausanne). 2021; 8: 682547. https://doi.org/10.3389/fmed.2021.682547

16. Li C., Sun X., Zhao K., Meng F., Li L., Mu Z., et al. Efficacy and safety of janus kinase inhibitors for the treatment of atopic dermatitis: a systematic review and meta-analysis. Dermatology. 2022; 238(4): 725–35. https://doi.org/10.1159/000518541

17. Bao L., Zhang H., Chan L.S. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. JAKSTAT. 2013; 2(3) e24137. https://doi.org/10.4161/jkst.24137

18. Novikov P.I., Shevtsova T.P., Shchegoleva E.M., Moiseev S.V. Janus kinase inhibitors: pharmacological properties and comparative clinical efficacy and safety. Klinicheskaya farmakologiya i terapiya. 2021; 30(1): 51–60. https://doi.org/10.32756/0869-5490-2021-1-51-60 (in Russian)

19. Blauvelt A., Teixeira H.D., Simpson E.L., Costanzo A., De Bruin-Weller M., Barbarot S., et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021; 157(9): 1047–55. https://doi.org/10.1001/jamadermatol.2021.3023

20. Nezamololama N., Fieldhouse K., Metzger K., Gooderham M. Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib. Drugs Context. 2020; 9: 2020-8-5. https://doi.org/10.7573/dic.2020-8-5

21. Guttman-Yassky E., Thaçi D., Pangan A.L., Hong H.C., Papp K.A., Reich K., et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J. Allergy Clin. Immunol. 2020; 145(3): 877–84. https://doi.org/10.1016/j.jaci.2019.11.025

22. Ferreira S., Guttman-Yassky E., Torres T. Selective JAK1 inhibitors for the treatment of atopic dermatitis: focus on upadacitinib and abrocitinib. Am. J. Clin. Dermatol. 2020; 21(6): 783–98. https://doi.org/10.1007/s40257-020-00548-6

23. Guttman-Yassky E., Teixeira H.D., Simpson E.L., Papp K.A., Pangan A.L., Blauvelt A., et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021; 397(10290): 2151–68. https://doi.org/10.1016/S0140-6736(21)00588-2

24. Simpson E.L., Papp K.A., Blauvelt A., Chu C.Y., Hong H.C., Katoh N., et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the measure up 1 and measure up 2 randomized clinical trials. JAMA Dermatol. 2022; 158(4): 404–13. https://doi.org/10.1001/jamadermatol.2022.0029

25. Nogueira M., Torres T. Janus kinase inhibitors for the treatment of atopic dermatitis: focus on abrocitinib, baricitinib, and upadacitinib. Dermatol. Pract. Concept. 2021; 11(4): e2021145. https://doi.org/10.5826/dpc.1104a145

26. Reich K., Teixeira H.D., de Bruin-Weller M., Bieber T., Soong W., Kabashima K., et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021; 397(10290): 2169–81. https://doi.org/10.1016/S0140-6736(21)00589-4

27. Silverberg J.I., de Bruin-Weller M., Bieber T., Soong W., Kabashima K., Costanzo A., et al. Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results. J. Allergy Clin. Immunol. 2022; 149(3): 977–87.e14. https://doi.org/10.1016/j.jaci.2021.07.036

28. Shalabi M.M.K., Garcia B., Coleman K., Siller A.Jr., Miller A.C., Tyring S.K. Janus kinase and tyrosine kinase inhibitors in dermatology: a review of their utilization, safety profile and future applications. Skin Therapy Lett. 2022; 27(1): 4–9.